Naturewise Biotech & MedicalsROCO:4732 62 Gross Margin % is 47.20% as of Dec. 2025, which is 13% below its 10-year median of 54.11. GuruFocus rates ROCO:4732 with a GF Score™ of 62/100 and a GF Value™ of NT$22.11 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Naturewise Biotech & Medicals ranks worse than 61.61% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Naturewise Biotech & Medicals had a gross margin of 47.20% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Naturewise Biotech & Medicals Gross Margin % Related Terms
Naturewise Biotech & Medicals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4732 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Naturewise Biotech & Medicals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturewise Biotech & Medicals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Naturewise Biotech & Medicals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Naturewise Biotech & Medicals (ROCO:4732) has a Gross Margin % of 47.20% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Naturewise Biotech & Medicals and its competitors. This is 13% below median its historical median of 54.11. Over the past decade, Naturewise Biotech & Medicals' Gross Margin % has ranged from 45.25 to 59.77. According to the industry distribution chart, Naturewise Biotech & Medicals ranks #451 out of 732 companies in the Biotechnology industry, placing it in the top 61.6%.
Is Naturewise Biotech & Medicals' Gross Margin % too high?
Naturewise Biotech & Medicals' current Gross Margin % of 47.20% is 13% below median its 10-year median of 54.11. Over the past 10 years, this metric has ranged from a low of 45.25 to a high of 59.77. The Biotechnology industry median Gross Margin % is 60.91. Naturewise Biotech & Medicals' value of 47.20% is 22.5% below this industry median. Based on the distribution chart, Naturewise Biotech & Medicals ranks #451 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Naturewise Biotech & Medicals has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Naturewise Biotech & Medicals ranks #451 out of 732 companies for Gross Margin %. This places Naturewise Biotech & Medicals in the lower half of its industry. The industry median Gross Margin % is 60.91. Naturewise Biotech & Medicals' value of 47.20% is 22.5% below this benchmark. Historically, Naturewise Biotech & Medicals' own Gross Margin % has ranged from 45.25 to 59.77 over the past decade. While the company's 10-year median is 54.11 vs. the industry median of 60.91, Naturewise Biotech & Medicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturewise Biotech & Medicals's current Gross Margin % of 47.20% is 22.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Naturewise Biotech & Medicals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturewise Biotech & Medicals's current Gross Margin % is 47.20%, which is 13% below median its own 10-year median of 54.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.11, compared to a current price of NT$17.00 — trading 23.1% below its estimated fair value. The current Gross Margin % is 47.20%, which is 13% below median its 10-year median of 54.11 and 22.5% below the Biotechnology industry median of 60.91. Naturewise Biotech & Medicals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Gross Margin % is 47.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued.
The current stock price of NT$17.00 is trading 23.1% below its estimated GF Value™ of NT$22.11.
GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.
Key valuation signals for ROCO:4732:
Gross Margin %: 47.20% (13% below median its 10-year median of 54.11)
GF Value™: NT$22.11 vs. price of NT$17.00 (23.1% below fair value)
Industry Position: 22.5% below the Biotechnology median (#451 of 732)
No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturewise Biotech & Medicals Business Description
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
62GF Score
Get the complete analysis for ROCO:4732
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4732 has been successfully added to your 
